Impact of Wnt/β-Catenin Inhibition on Cell Proliferation through <i>CDC25A</i> Downregulation in Soft Tissue Sarcomas

• Main Authors: Esther Martinez-Font, Marina Pérez-Capó, Rafael Ramos, Irene Felipe, Carmen Garcías, Pablo Luna, Josefa Terrasa, Javier Martín-Broto, Oliver Vögler, Regina Alemany, Antònia Obrador-Hevia
• Format: Article
• Language: English
• Published: MDPI AG 2020-09-01
• Series: Cancers
• Subjects: soft tissue sarcoma; Wnt signaling; β-catenin; CDC25A; PRI-724
• Online Access: https://www.mdpi.com/2072-6694/12/9/2556

The Wnt signaling pathway is an important cellular mechanism for regulating differentiation processes as well as cell cycle events, and different inhibitors of this pathway, for example, PRI-724, are showing promising results in clinical trials for treatment of advanced pancreatic adenocarcinoma or ovarian cancer. Growing evidence suggests that Wnt signaling may also be crucial for tumorigenesis and progression of soft tissue sarcomas (STS), a malignant neoplasm with few therapeutic options at an advanced state. Our study with several STS cell lines and primary cultures shows that inhibition of Wnt/β-catenin signaling with PRI-724 is able to suppress cell viability/proliferation and to increase cell death rates. TCF/β-catenin-mediated transcriptional activity is decreased in treated cells, leading to downregulation of its target genes <i>CCND1</i> and <i>CDC25A.</i> The latter was critical because its downregulation via siRNA was able to mimic the effect of PRI-724 on cell cycle arrest and cell death induction. An evaluation of NCBI/GenBank data confirmed that <i>CDC25A</i> mRNA is elevated in STS patients. Importantly, PRI-724 in combination with standard STS chemotherapeutics doxorubicin or trabectedin enhanced their antitumoral effect in a synergistic manner according to isobolographic analysis, suggesting that Wnt inhibition through PRI-724 could be a beneficial combination regime in patients with advanced STS.